CytoDyn (CYDY) Notes Payables (2013 - 2024)

CytoDyn's (CYDY) quarterly Notes Payables came in at $3.5 million in Q1 2024, up 10484.85% on a QoQ basis from $33000.0 in Q4 2023.

CytoDyn (CYDY) Notes Payables (2013 - 2024) Analysis & Trends

CytoDyn (CYDY) has 9 years of Notes Payables data on file, last reported at $3.5 million in Q1 2024.

Quarterly Notes Payables changed N/A year-over-year to $3.5 million in Q1 2024, while the trailing twelve-month figure through Feb 2024 was $3.5 million (changed N/A YoY) and the FY2023 annual result came in at $79000.0, changed N/A from the prior year.
Notes Payables climbed to $3.5 million in Q1 2024, from $33000.0 in the prior quarter.
In the past five years, Notes Payables ranged from a high of $5.2 million in Q2 2020 to a low of $33000.0 in Q4 2023.
A 3-year average of $2.8 million and a median of $3.7 million in 2020 frame the typical range for Notes Payables.
The widest YoY moves for Notes Payables: up 72.39% in 2020, down 45.01% in 2020.
Tracing CYDY's Notes Payables over 3 years: stood at $5.2 million in 2020, then tumbled by 99.37% to $33000.0 in 2023, then surged by 10484.85% to $3.5 million in 2024.
The last three Notes Payables figures came in at $3.5 million (Q1 2024), $33000.0 (Q4 2023), and $4.4 million (Q3 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	CytoDyn	258.01 Mn	258.01 Mn	-

Download Data